Trial reportThe American journal of clinical nutrition2026
Leucine supplementation does not attenuate the decline in daily muscle protein synthesis rates or preserve leg muscle mass during leg immobilization in young or older adults: a double-blind randomized trial.
Trial report in The American journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbial-derived Exerkines preserve muscle size and function during disuse in aged mice in a sex-dependent manner.Physiological reports · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMuscle disuse leads to muscle atrophy that has been attributed to declines in basal and postprandial muscle protein synthesis (MPS) rates. Leucine regulates MPS and may attenuate disuse-induced declines in MPS rates and muscle mass.
objectivesThe purpose of this study was to evaluate the capacity of leucine supplementation to attenuate disuse-induced declines in MPS rates and muscle mass in young and older adults.
methodsIn a randomized, double-blind, parallel-group design, 24 young (23 ± 4 y) and 24 older (69 ± 4 y) recreationally active adults (equal sex distribution) underwent 3 d of unilateral knee immobilization (leg casting) and received a leucine [group of adult study participants who supplemented with 5 g of leucine 3 × daily with each main meal during 3 d of unilateral knee immobilization by means of a full leg cast (LEU)] or energy-matched carbohydrate [group of adult study participants who supplemented with 5 g of carbohydrate 3 × daily with each main meal during 3 d of unilateral knee immobilization by means of a full leg cast (PLA)] supplement. Preimmobilization and postimmobilization, quadriceps muscle cross-sectional area (CSA) was assessed in the immobilized (IM) and nonimmobilized (NO-IM) leg by computed tomography. MPS rates were assessed in both legs during immobilization via
resultsIn young and older adults, MPS rates were ∼15% and ∼23% lower in the IM compared with NO-IM leg (1.28 ± 0.29 compared with 1.50 ± 0.26 and 1.10 ± 0.16 compared with 1.46 ± 0.28%/d, respectively; leg: both P < 0.001), with no differences between LEU compared with PLA treatments (treatment: P = 0.932 and P = 0.742, respectively). CSA decreased by ∼1.2% and ∼1.1% in the IM leg in young and older adults (from 7162 ± 1148 to 7076 ± 1129 mm
conclusionsLeucine supplementation does not attenuate the decline in daily MPS rates or muscle mass during short-term limb immobilization in young or older adults. Clinical Trial Register No. (Netherlands Trial Register): NL-OMON45771.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.